
|Articles|February 1, 2004
STAAR Surgical revamps procedures after FDA warning; product complaints at issue
Monrovia, CA-Officials at STAAR Surgical Co. are scrambling to answer questions raised by a warning letter from the FDA that criticized the company for failing to review product complaints adequately and ensure quality control of its manufacturing materials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
3
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
4
Q&A: Understanding Medicare payment shifts in eye care
5














































